Overview

Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis

Status:
Unknown status
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of multiple intravenous doses of pegol-Sihematide in participants with chronic kidney disease (CKD) who are on dialysis.
Phase:
Phase 2
Details
Lead Sponsor:
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Treatments:
Epoetin Alfa